- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
All News
Barriers of Treating EGFR-Mutant NSCLC With Adjuvant Osimertinib
July 23, 2021
Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.
Oral MDM2 Inhibitor Milademetan Enters Phase 3 Study for Patients with De-Differentiated Liposarcoma
July 22, 2021
A phase 3 study has been initiated in order to evaluate the efficacy of the oral MDM2 inhibitor milademetan for the treatment of de-differentiated liposarcoma.
Overall Survival Results of I/O Combinations Differ Across Risk Groups of Metastatic RCC
July 22, 2021
The overall survival benefit of immunotherapy combinations compared with sunitinib for the treatment of patients with metastatic renal cell carcinoma who have favorable risk may differ from those who have intermediate or poor risk, according to a pooled analysis of frontline combination therapy conducted by the FDA.
Survival Improvement Not Shown With Adjuvant Chemotherapy in Locally Adnvaced Cervical Cancer
July 22, 2021
In an interview with Targeted Oncology, Bradley Monk, MD, FACCOG, FACS, discusses the OUTBACK trial, including the results, strengths, and challenges.
SITC Releases Clinical Practice Guideline to Aid in the Management of Immune-Related Adverse Events from ICI Therapy
July 22, 2021
Based on a review of immune checkpoint inhibitor mechanisms of action and clinical trial data, SITC has published a clinical practice guideline, which provides key recommendations for managing immune-related adverse events.
FDA Approves Lenvatinib/Pembrolizumab for Select Patients With Advanced Endometrial Cancer
July 22, 2021
The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.
Tripathy Discusses the Use of HER2-Positive Breast Cancer Agents Across Other Cancer Types
July 22, 2021
Debu Tripathy, MD, discusses the use of tucatinib, capecitabine, and trastuzumab for the treatment of patients with HER2-positive breast cancer and leptomeningeal disease in other HER2-positive cancer types.
Precise Management of EGFR exon 20-Positive Non–Small Cell Lung Cancer
July 21, 2021
Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.
Atezolizumab Is Linked to Improvement in DFS in Early-Stage NSCLC
July 21, 2021
Adjuvant treatment with atezolizumab led to a significant improvement in disease-free survival versus supportive care in patients with PD-L1–positive non–small cell lung cancer.
UriFind Test for Bladder Cancer Granted FDA Breakthrough Device Designation
July 21, 2021
The UriFind test that utilizes DNA methylation detection for the diagnosis of bladder cancer has been granted a breakthrough device designation by the FDA.